Patient P-01436
Therapy response
Unstable
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Unstable
Nutritional resilience
Stable
Discontinuation risk
76%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 53 GI-04 recommended — GI Support Protocol GI-04
- Day 54 Patient accepted — Started GI-04 in the companion
- Day 58 ME-01 recommended — Monitoring Escalation ME-01
- Day 59 Patient accepted — Started ME-01 in the companion
- Day 62 GI symptom burden −34% vs expected — GI Support Protocol GI-04
- Day 62 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 68 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- Inflammatory activity+18
- GI instability+7
- Treatment adherence+4
- Nutritional resilience-2
What helped?
- GI Support Protocol GI-04Day 53Result: symptom burden −34%
- Monitoring Escalation ME-01Day 58Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
63%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 54 and rising
- WearableSleep 5.6 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 39/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 60
- Autonomic recovery ↓45
- WearableResting HR 82 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 50
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.5 · butyrate capacity 39/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 6.0 h
- Steps
- 6,173
- Resting HR
- 82 bpm
Daily log: GI score 54, nutritional resilience 44, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01781 | 60% | S14 | NP-02 | improved | 45 |
| P-01505 | 53% | S14 | NP-02 | improved | 41 |
| P-01356 | 52% | S14 | GI-04 | improved | 42 |
| P-01556 | 52% | S14 | GI-04 | improved | 44 |
| P-01307 | 51% | S14 | GI-04 | improved | 43 |
| P-01389 | 51% | S14 | SC-12 | improved | 46 |
| P-01675 | 51% | S14 | NP-02 | improved | 38 |
| P-01845 | 51% | S14 | NP-02 | improved | 47 |
| P-01413 | 50% | S14 | GI-04 | improved | 44 |
| P-01494 | 50% | S14 | GI-04 | improved | 42 |
| P-01570 | 50% | S14 | SC-12 | improved | 46 |
| P-01581 | 50% | S18 | GI-04 | improved | 51 |